CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial.

Genet Med 2019 08 23;21(8):1842-1850. Epub 2019 Jan 23.

Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA.

Purpose: CYP2D6 bioactivates codeine and tramadol, with intermediate and poor metabolizers (IMs and PMs) expected to have impaired analgesia. This pragmatic proof-of-concept trial tested the effects of CYP2D6-guided opioid prescribing on pain control.

Methods: Participants with chronic pain (94% on an opioid) from seven clinics were enrolled into CYP2D6-guided (n = 235) or usual care (n = 135) arms using a cluster design. CYP2D6 phenotypes were assigned based on genotype and CYP2D6 inhibitor use, with recommendations for opioid prescribing made in the CYP2D6-guided arm. Pain was assessed at baseline and 3 months using PROMIS measures.

Results: On stepwise multiple linear regression, the primary outcome of composite pain intensity (composite of current pain and worst and average pain in the past week) among IM/PMs initially prescribed tramadol/codeine (n = 45) had greater improvement in the CYP2D6-guided versus usual care arm (-1.01 ± 1.59 vs. -0.40 ± 1.20; adj P = 0.016); 24% of CYP2D6-guided versus 0% of usual care participants reported ≥30% (clinically meaningful) reduction in the composite outcome. In contrast, among normal metabolizers prescribed tramadol or codeine at baseline, there was no difference in the change in composite pain intensity at 3 months between CYP2D6-guided (-0.61 ± 1.39) and usual care (-0.54 ± 1.69) groups (adj P = 0.540).

Conclusion: These data support the potential benefits of CYP2D6-guided pain management.

Download full-text PDF

Source
http://www.nature.com/articles/s41436-018-0431-8
Publisher Site
http://dx.doi.org/10.1038/s41436-018-0431-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650382PMC
August 2019
46 Reads

Publication Analysis

Top Keywords

usual care
16
pain
9
cyp2d6-guided versus
8
poor metabolizers
8
opioid prescribing
8
pain intensity
8
cyp2d6-guided
8
composite pain
8
intermediate poor
8
versus usual
8
cyp2d6-guided opioid
8
benefits cyp2d6-guided
4
intensity composite
4
composite current
4
cyp2d6-guided pain
4
outcome composite
4
regression primary
4
primary outcome
4
composite
4
current pain
4

References

(Supplied by CrossRef)

RL Nahin et al.
J Pain 2015

B Levy et al.
Am J Prev Med 2015

BK Madras et al.
JAMA Psychiatry 2017

KR Crews et al.
Clin Pharmacol Ther 2014

DA Volpe et al.
Regul Toxicol Pharmacol 2011

K Eckhardt et al.
Pain 1998

J Lotsch et al.
Pain 2009

L Poulsen et al.
Clin Pharmacol Ther 1996

UM Stamer et al.
Clin Pharmacol Ther 2007

J Lotsch et al.
Clin Pharmacol Ther 2006

Similar Publications